Nutrition and nutraceutical supplements in the treatment of hypertension

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 6, 2010, Pages 821-833

  Houston, Mark C ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Antioxidants; Hypertension; Natural treatment; Nutrition; Vascular biology

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ARGININE; ASCORBIC ACID; CAFFEINE; CALCIUM; CARNITINE; FAT; FLAVONOID; LYCOPENE; MAGNESIUM; MINERAL; NUTRACEUTICAL; OMEGA 3 FATTY ACID; POTASSIUM; PROTEIN; PYCNOGENOL; PYRIDOXINE; REACTIVE OXYGEN METABOLITE; SODIUM; TAURINE; THIOCTIC ACID; UBIDECARENONE; VITAMIN; VITAMIN D; ZINC; ANTIHYPERTENSIVE AGENT;

ALCOHOL ABSTINENCE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIET RESTRICTION; DIET SUPPLEMENTATION; DIETARY FIBER; DIETARY INTAKE; DISEASE COURSE; DISEASE SEVERITY; EXERCISE; FAT INTAKE; FIBER; GARLIC; GENE INTERACTION; HEALTH CARE COST; HEALTH STATUS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIFESTYLE MODIFICATION; NUTRITIONAL SUPPORT; ORGAN INJURY; OXIDATIVE STRESS; PHENOTYPE; PHENOTYPIC VARIATION; PROTEIN INTAKE; REVIEW; SEAWEED; SMOKING CESSATION; STROKE; TARGET ORGAN; TEA; VASCULAR BIOLOGY; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION; ANIMAL; CARDIOVASCULAR DISEASES; DIET; DIET THERAPY; DRUG EFFECTS; LIFESTYLE; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; DIET; DIETARY SUPPLEMENTS; HUMANS; HYPERTENSION; LIFE STYLE; NUTRITIONAL STATUS; OXIDATIVE STRESS; RISK FACTORS;

EID: 77953498264     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.63     Document Type: Review

References (102)

1. Houston MC. Treatment of hypertension with nutraceuticals. Vitamins, antioxidants and minerals. Expert Rev. Cardiovasc. Ther. 5(4), 681-691 (2007).
2. Eaton SB, Eaton SB III, Konner MJ. Paleolithic nutrition revisited: a twelve-year retrospective on its nature and implications. Eur. J. Clin. Nutr. 51, 207-216 (1997).
3. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7). JAMA 289, 2560-2572 (2003).
4. Houston MC. New insights and approaches to reduce end organ damage in the treatment of hypertension: subsets of hypertension approach. Am. Heart J. 123, 1337-1367 (1992).
5. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in six European countries, Canada and the United States. JAMA 289, 2363-2369 (2003)
6. Nayak DU, Karmen C, Frishman WH, Vakili BA. Antioxidant vitamins and enzymatic and synthetic oxygen-derived free radical scavengers in the prevention and treatment of cardiovascular disease. Heart Dis. 3, 28-45 (2001).
7. Kitiyakara C, Wilcox C. Antioxidants for hypertension. Curr. Opin. Nephrol. Hypertens. 7, 531-538 (1998).
8. Russo C, Olivieri O, Girelli D et al. Antioxidant status and lipid peroxidation in patients with essential hypertension. J. Hypertens. 16, 1267-1271 (1998).
9. Tse WY, Maxwell SR, Thomason H et al. Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial damage. J. Hum. Hypertens. 8, 843-849 (1994).
10. Galley HF, Thornton J, Howdle PD, Walker BE, Webster NR. Combination oral antioxidant supplementation reduces blood pressure. Clin. Sci. 92, 361-365 (1997).
11. Dhalla NS, Temsah RM, Netticadam T. The role of oxidative stress in cardiovascular diseases. J. Hypertens. 18, 655-673 (2000).
12. Saez G, Tormos MC, Giner V, Lorano JV, Chaves FJ. Oxidative stress and enzymatic antioxidant mechanisms in essential hypertension. Am. J. Hypertens. 14, 248A (2001) (Abstract P-653).
13. Eaton SB, Eaton SB III, Konner MJ. Paleolithic nutrition revisited: a twelve-year retrospective on its nature and implications. Eur. J. Clin. Nutr. 51, 207-216 (1997).
14. Berdanier CD. Nutrient-gene interactions. In: Present Knowledge in Nutrition (7th Edition). Ziegler EE, Filer LJ Jr (Eds). ILSI Press, Washington DC, USA, 574-580 (1996).
15. Talmud PJ, Waterworth DM. In vivo and in vitro nutrient-gene interactions. Curr. Opin. Lipidol. 11, 31-36 (2000).
16. Broadhurst CL. Balanced intakes of natural triglycerides for optimum nutrition: an evolutionary and phytochemical perspective. Med. Hypoth. 49, 247-261 (1997).
17. Kotchen TA, McCarron DA. AHA Science Advisory. Dietary electrolytes and blood pressure. Circulation 98, 613-617 (1998).
18. Cutler JA, Follmann, Allender PS. Randomized trials of sodium reduction: an overview. Am. J. Clin. Nutr. 65, 643S-651S (1997).
19. Svetkey LP, Sacks FM, Obarzanek E et al. The DASH diet, sodium intake and blood pressure (the DASH-Sodium Study): rationale and design. J. Am. Diet. Assoc. 99, S96-S104 (1999).
20. Messerli FH, Schmieder RE, Weir MR. Salt: a perpetrator of hypertensive target organ disease? Arch. Intern. Med. 157, 2449-2452 (1997).
21. Kawasaki T, Delea CS, Bartter FC, Smith H. The effect of high-sodium and low-sodium intakes on blood pressure and other related variables in human subjects with idiopathic hypertension. Am. J. Med. 64, 193-198 (1978).
22. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension 27, 481-490 (1996).
23. Morimoto A, Usu T, Fujii T et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 350, 1734-1737 (1997).
24. Houston MC, Harper KJ. Potassium, magnesium, and calcium: their role in both the cause and treatment of hypertension. J. Clin. Hypertens. 10(7 Suppl. 2), 3-11 (2008).
25. Whelton PK, He J. Potassium in preventing and treating high blood pressure. Semin. Nephrol. 19, 494-499 (1999).
26. Gu D, He J, Xigui W, Duan X, Whelton PK. Effect of potassium supplementation on blood pressure in Chinese: a randomized, placebo-controlled trial. J. Hypertens. 19, 1325-1331 (2001).
27. Widman L, Wester PO, Stegmayr BG, Wirell MP. The dose dependent reduction in blood pressure through administration of magnesium: a double blind placebo controlled cross-over trial. Am. J. Hypertens. 6, 41-45 (1993).
28. Laurant P, Touyz RM. Physiological and pathophysiological role of magnesium in the cardiovascular system: implications in hypertension. J. Hypertens. 18, 1177-1191 (2000).
29. McCarron DA. Role of adequate dietary calcium intake in the prevention and management of salt sensitive hypertensive. Am. J. Clin. Nutr. 65, 712S-716S (1997).
30. Resnick LM. Calcium metabolism in hypertension and allied metabolic disorders. Diabetes Care 14, 505-520 (1991).
31. Garcia Zozaya JL, Padilla Viloria M. Alterations of calcium, magnesium, and zinc in essential hypertension: their relation to the rennin-angiotensin- aldosterone system. Invest. Clin. 38, 27-40 (1997).
32. Bergomi M, Rovesti S, Vinceti M et al. Zinc and copper status and blood pressure. J. Trace Elem. Med. Biol. 11, 166-169 (1997).
33. Stamler J, Elliott P, Kesteloot H et al. Inverse relation of dietary protein markers with blood pressure. Findings for 10,020 men and women in the Intersalt Study. Intersalt Cooperative Research Group. International study of salt and blood pressure. Circulation 94, 1629-1634 (1996).
34. Elliott P, Dennis B, Dyer AR et al. Relation of dietary protein (total, vegetable, animal) to blood pressure: INTERMAP epidemiologic study. Presented at: 18th Scientific Meeting of the International Society of Hypertension. Chicago, IL, USA, 20-24 August 2000.
35. FitzGerald RJ, Murray BA, Walsh DJ. Hypotensive peptides from milk proteins. J. Nutr. 134(4), 980S-988S (2004).
36. Pins JJ, Keenan JM. Effects of whey peptides on cardiovascular disease risk factors. J. Clin. Hypertens. 8(11), 775-782 (2006).
37. Aihara K, Kajimoto O, Takahashi R, Nakamura Y. Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J. Am. Coll. Nutr. 24(4), 257-265 (2005).
38. Pins J, Keenan J. The antihypertensive effects of a hydrolyzed whey protein supplement. Cardiovasc. Drugs Ther. 16(Suppl.), 68 (2002).
39. Kawasaki T, Seki E, Osajima K et al. Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects. J. Hum. Hypertens. 14, 519-523 (2000).
40. Kawasaki T, Jun CJ, Fukushima Y, Seki E. Antihypertensive effect and safety evaluation of vegetable drink with peptides derived from sardine protein hydrolysates on mild hypertensive, high-normal and normal blood pressure subjects. Fukuoka Igaku Zasshi 93(10), 208-218 (2002).
41. Begg DP, Sinclari AJ, Stahl LA, Garg ML, Jois M, Weisinger RS. Dietary proteins level interacts with omega-3 polyunsaturated fatty acid deficiency to induce hypertension. Am. J. Hypertens. 23(2), 125-128 (2009).
42. Morris MC. Dietary fats and blood pressure. J. Cardiovasc. Risk 1, 21-30 (1994).
43. Mori TA, Bao DQ, Burke V, Puddey IB, Beilin LJ. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 34, 253-260 (1999).
44. Bønaa KH, Bjerve KS, Straume B, Gram IT, Thelle D. Effect of eicosapentaenoic and docosahexanoic acids on blood pressure in hypertension: a population-based intervention trial from the Tromso study. N. Engl. J. Med. 322, 795-801 (1990).
45. Mori TA, Burke V, Puddey I, Irish A. The effects of omega 3 fatty acids and coenzyme Q 10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J. Hypertens. 27(9), 1863-1872 (2009).
46. Ueshima H, Stamler J, Elliot B, Brown, CQ. Food omega 3 fatty acid intake of individuals (total, linolenic acid, long chain) and their blood pressure: INTERMAP study. Hypertension 50(2), 313-319 (2007).
47. Mon TA. Omega 3 fatty acids and hypertension in humans. Clin. Exp. Pharmacol. Physiol. 33(9), 842-846 (2006).
48. Eaton SB, Eaton SB III, Konner MJ. Paleolithic nutrition revisited: a twelve-year retrospective on its nature and implications. A review. Eur. J. Clin. Nutr. 51, 207-216 (1997).
49. Chin JP. Marine oils and cardiovascular reactivity. Prostaglandins Leukot. Essent. Fatty Acids 50, 211-222 (1994).
50. Ferrara LA, RaimondiS, d'Episcopa I. Olive oil and reduced need for antihypertensive medications. Arch. Intern. Med. 160, 837-842 (2000).
51. Thomsen C, Rasmussen OW, Hansen KW, Vesterlund M, Hermansen K. Comparison of the effects on the diurnal blood pressure, glucose, and lipid levels of a diet rich in monounsaturated fatty acids with a diet rich in polyunsaturated fatty acids in Type 2 diabetic subjects. Diabet. Med. 12, 600-606 (1995).
52. He J, Whelton PK. Effect of dietary fiber and protein intake on blood pressure: a review of epidemiologic evidence. Clin. Exp. Hypertens. 21, 785-796 (1999).
53. Simons S, Wollersheim H, Thien T. A systematic review on the influence of trial quality on the effets of garlic on blood pressure. Neth. J. Med. 67(6), 212-219 (2009).
54. Reinhard KM, Coleman CI, Teevan C, Vacchani P. Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysis. Ann. Pharmacother. 42 (12), 1766-1771 (2008).
55. Hodgson JM, Puddey IB, Burke V, Beilin LJ, Jordan N. Effects on blood pressure of drinking green and black tea. J. Hypertens. 17, 457-463 (1999).
56. Suetsuna K, Nakano T. Identification of an antihypertensive peptide from peptic digest of wakame (Undaria pinnatifida). J. Nutr. Biochem. 11, 450-454 (2000).
57. Nakano T, Hidaka H, Uchida J, Nakajima K, Hata Y. Hypotensive effects of wakame. J. Jpn Soc. Clin. Nutr. 20, 92 (1998).
58. Krotkiewski M, Aurell M, Holm G, Grimby G, Szckepanik J. Effects of a sodium-potassium ion-exchanging seaweed preparation in mild hypertension. Am. J. Hypertens. 4, 483-488 (1991).
59. Sherman DL, Keaney JF, Biegelsen ES et al. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension 35, 936-941 (2000).
60. Ness AR, Khaw K-T, Bingham S, Day NE. Vitamin C status and blood pressure. J. Hypertens. 14, 503-508 (1996).
61. Duffy SJ, Bokce N, Holbrook M et al. Treatment of hypertension with ascorbic acid. Lancet 354, 2048-2049 (1999).
62. Enstrom JE, Kanim LE, Klein M. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 3, 194-202 (1992).
63. Block G, Jensen, CD, Norkus EP, Hudes M, Crawford PB. Vitamin C in plasma is inversely related to blood pressure and change in blood pressure during the previous year in young black and white women. Nutr. J. 17(7), 35-46 (2008).
64. Hatzitolios A, Iliadis F, Katsiki N, Baltatzi M. Is the antihypertensive effet of dietary supplements via aldehydes reduction evidence based: a systemic review. Clin. Exp. Hypertens. 30(7), 628-639 (2008).
65. Mahajan AS, Babbar R, Kansai N, Agarwai SK, Ray PC. Antihypertensive and antioxidant action of amlodipine and Vitamin C in patients of essential hypertension. J. Clin. Biochem. Nutr. 402, 141-147 (2007).
66. Ledlerc PC, Proulx, CD, Arquin G, Belanger S. Ascorbic acid decreases the binding affinity of the AT1 receptor for angiotensin II. Am. J. Hypertens. 21(1), 67-71 (2009).
67. Plantinga Y, Ghiadone L, Magagna A, Biannarelli C. Supplementation with Vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am. J. Hypertens. 20(4), 392-397 (2007).
68. Sato K, Dohi Y, Kojima M, Miyagawa K. Effects of ascorbic acid on ambulatory blood pressure in elderly patients with refractory hypertension. Arzneimittelforschung 56(7), 535-540 (2006).
69. Block G, Mangels AR, Norkus EP, Patterson BH, Levander OA, Taylor PR. Ascorbic acid status and subsequent diastolic and systolic blood pressure. Hypertension 37, 261-267 (2001).
70. National Center for Health Statistics; Fulwood R, Johnson CL, Bryner JD. Hematological and Nutritional Biochemistry Reference Data for Persons 6 Months-74 Years of Age: United States, 1976-1980. US Public Health Service, Washington DC, USA, Vital and Health Statistics series 11, No.232, DHHS publication No. (PHS) 83-1682 (1982).
71. Ward NC, Wu JH, Clarke MW, Buddy IB. Vitamin E effects on the treatment of hypertension in Type 2 diabetics. J. Hypertens. 227, 227-234 (2007).
72. Hanni LL, Huarfner LH, Sorensen OH, Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am. J. Hypertens. 8, 894-901 (1995).
73. Bednarski R, Donderski R, Manitius L. Role of vitamin D in arterial blood pressure control. Pol. Merkur. Lekarski 136, 307-310 (2007).
74. Li YC, Kong H, Wei M, Chen ZF. 1, 25 Dihydroxyvitamin D 3 is a negative endocrine regulator of the renin angiotensin system. J. Clin. Invest. 110(2), 229-238 (2002).
75. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J. Clin. Endocrinol. Metab. 86, 1633-1637 (2001).
76. Keniston R, Enriquez JI Sr. Relationship between blood pressure and plasma vitamin B6 levels in healthy middle-aged adults. Ann. NY Acad. Sci. 585, 499-501 (1990).
77. Aybak M, Sermet A, Ayyildiz MO, Karakilcik AZ. Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension. Arzneimittelforschung 45, 1271-1273 (1995).
78. Moline J, Bukharovich IF, Wolff MS, Phillips R. Dietary flavonoids and hypertension: is there a link? Med. Hypotheses 55, 306-309 (2000).
79. Knekt P, Reunanen A, Järvinen R, Seppänen R, Heliövaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am. J. Epidemiol. 139, 1180-1189 (1994).
80. Karatzi KN, Papamichael CM, Karatizis EN et al. Red wine acutely induces favorable effects on wave reflections and central pressures in coronary artery disease patients. Am. J. Hypertens. 18(9), 1161-1167 (2005).
81. Paran E, Engelhard YN. Effect of lycopene, an oral natural antioxidant on blood pressure. J. Hypertens. 19, S74 (2001) (Abstract P 1.204).
82. Engelhard YN, Gazer B, Paran E. Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: a double blind placebo controlled pilot study. Am. Heart J. 151(1), 100 (2006).
83. Paran E, Novac C, Engelhard YN, Hazan-Halevy I. The effects of natural antioxidants form tomato extract in treated but uncontrolled hypertensive patients. Cardiovasc. Drugs Ther. 23(2), 145-151 (2009).
84. Reid K, Frank OR, Stocks NP. Dark chocolate or tomato extract for prehypertension: a randomized controlled trial. BMC Complement. Altern Med. 9, 22 (2009).
85. Paran E, Engelhard Y. Effect of tomato's lycopene on blood pressure, serum lipoproteins, plasma homocysteine and oxidative stress markers in grade I hypertensive patients. Am. J. Hypertens. 14, 141A (2001) (Abstract P-333).
86. Langsjoen PH, Langsjoen AM. Overview of the use of Co Q 10 in cardiovascular disease. Biofactors 9, 273-284 (1999).
87. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressure and insulin resistance in hypertensive patients with coronary heart disease. J. Hum. Hypertens. 12, 203-208 (1999).
88. Burke BE, Neustenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South. Med. J. 94, 1112-1117 (2001).
89. Rosenfeldt FL, Haas SJ, Krum H et al. Coenzyme Q 10 in the treatment of hypertension: a meta-analysis of the clinical tials. J. Hum. Hypertens. 21(4), 297-306 (2007).
90. Singh RB, Niaz MA, Rastogi SS, Shukia PK, Thakur AS. Effect of hydrosoluble coenzyme Q 10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J. Hum. Hypertens. 13(3), 302-308 (1999).
91. Ankola DD, Viswanas B, Bhardqaj V, Ramarao P, Kumar MN. Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nuttitional supplement be used as first line therapeutic agents for prophylaxis/therapy? Eur. J. Pharm. Biopharm. 67(2), 361-369 (2007).
92. McMackin CJ, Widlansky ME, Hambury NM, Haung AL. Effect of combined treatment with a-lipoic acid and acetyl carnitine on vascular function and blood pressure in patients with coronary artery disease. J. Clin. Hypertens. 9, 249-255 (2007).
93. Siani A, Pagano E, Iacone R, Iacoviell L, Scopacasa F, Strazzullo P. Blood pressure and metabolic changes during dietary l-arginine supplementation in humans. Am. J. Hypertens. 13, 547-551 (2000).
94. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethyl-arginine as an inhibitor of nitric oxide synthesis. J. Cardiovasc. Pharmacol. 20, S60-S62 (1992).
95. Digiesi V, Cantini F, Bisi G, Guarino G, Brodbeck B. l-carnitine adjuvant therapy in essential hypertension. Clin. Ter. 144, 391-395 (1994).
96. Huxtable RJ. Physiologic actions of taurine. Physiol. Rev. 72, 101-163 (1992).
97. Fujita T, Ando K, Noda H, Ito Y, Sato Y. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation 75, 525-532 (1987).
98. Huxtable RJ, Sebring LA. Cardiovascular actions of taurine. Prog. Clin. Biol. Res. 125, 5-37 (1983).
99. Tanabe Y, Urata H, Kiyonaga A et al. Changes in serum concentrations of taurine and other amino acids in clinical antihypertensive exercise therapy. Clin. Exp. Hypertens. 11, 149-165 (1989).
100. Hosseini S, Lee J, Sepulveda RT et al. A randomized, double-blind, placebo-controlled, prospective 16 week crossover study to determine the role of pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutr. Res. 21, 1251-1260 (2001).
101. Zibadi S, Rohdewald PJ, Park D, Watson RR. Reduction of cardiovascular risk factors in subjects with Type 2 diabetes by pycnogenol supplementation. Nutr. Res. 28(5), 315-320 (2008).
102. Liu X, Wei J, Tan F, Zhou S, Wurthwein G, Rohdewald P. Pycnogenol French maritime pine bark extract improves endothelial function of hypertensive patients. Life Sci. 74(7), 855-862 (2004). (Pubitemid 37501134)